We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Arthritis Interception in Patients with Psoriasis Treated with Guselkumab.
- Authors
Zabotti, Alen; Giovannini, Ivan; McGonagle, Dennis; De Vita, Salvatore; Stinco, Giuseppe; Errichetti, Enzo
- Abstract
Interestingly, growing evidence supports that patients with PsO go through three clinically silent and progressive stages before developing clinically evident PsA ("pre-PsA"), in a "multi-step PsO to PsA march" [[1]]. Keywords: Guselkumab; Interception; Psoriasis; Psoriatic arthritis EN Guselkumab Interception Psoriasis Psoriatic arthritis 5 8 4 01/24/22 20220101 NES 220101 Psoriatic arthritis (PsA) is one of the main extracutaneous manifestations of psoriasis (PsO), with 20-30% of patients with PsO developing this condition over time [[1]-[3]]. Notably, two categories of predictors for PsA development have been identified in patients with PsO, including medium/long-term (PsA development greater than 2 years) and short-term (PsA development within 2 years) predictors [[2]].
- Subjects
PSORIATIC arthritis; PSORIASIS; ARTHRITIS
- Publication
Dermatology & Therapy, 2022, Vol 12, Issue 1, p5
- ISSN
2193-8210
- Publication type
Article
- DOI
10.1007/s13555-021-00650-5